Aldeyra Therapeutics Enters Material Definitive Agreement
Ticker: ALDX · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $100,000,000, $75,000,000, $75,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Aldeyra Therapeutics signed a big deal on Aug 1st, filing shows.
AI Summary
On August 1, 2024, Aldeyra Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal executive offices are located in Lexington, MA.
Why It Matters
This filing indicates a significant new contract or partnership for Aldeyra Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-36332 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-1968197 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- August 1, 2024 (date) — Date of earliest event reported
- Lexington, MA (location) — Address of principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the nature of the material definitive agreement entered into by Aldeyra Therapeutics?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on August 1, 2024.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on August 1, 2024.
What is Aldeyra Therapeutics' state of incorporation?
Aldeyra Therapeutics, Inc. is incorporated in Delaware.
Where are Aldeyra Therapeutics' principal executive offices located?
Aldeyra Therapeutics' principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What other items are included in this 8-K filing besides the material definitive agreement?
This 8-K filing also includes Financial Statements and Exhibits.
Filing Stats: 1,077 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2024-08-01 16:11:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
- $100,000,000 — g a maximum aggregate offering price of $100,000,000 (the "Prior Sales Agreement"). The issu
- $75,000,000 — ny will be able to offer and sell up to $75,000,000 of its shares of Common Stock pursuant
- $75,000 — the Sales Agreement in an amount up to $75,000, in addition to certain ongoing legal e
Filing Documents
- d814773d8k.htm (8-K) — 29KB
- d814773dex11.htm (EX-1.1) — 206KB
- d814773dex51.htm (EX-5.1) — 9KB
- g814773g0726220822644.jpg (GRAPHIC) — 3KB
- g814773g0726220823411.jpg (GRAPHIC) — 6KB
- g814773snap1.jpg (GRAPHIC) — 4KB
- 0001193125-24-191518.txt ( ) — 443KB
- aldx-20240801.xsd (EX-101.SCH) — 3KB
- aldx-20240801_lab.xml (EX-101.LAB) — 18KB
- aldx-20240801_pre.xml (EX-101.PRE) — 11KB
- d814773d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Open Market Sale Agreement SM by and between the Company and Jefferies LLC, dated August 1, 2024. 5.1 Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. 23.1 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated: August 1, 2024